Evidence map›Paper›PMID 15145911›Full record

Trial reportHeart (British Cardiac Society)2004

Treating to hypertension targets.

A McKerracher

Abstract readClinical TrialMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Heart (British Cardiac Society), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

A McKerracherSt Mary's Hospital, Praed Street, London W2 1NY, UK. a.mckerracher@imperial.ac.uk

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Control of blood pressure levels in hypertensive patients often fails to meet the targets suggested by the British Hypertension Society (BHS) guidelines. The optimal treatment target for non-diabetic patients is < or = 140/85 mm Hg. Data from the health survey for England show that in 1998 only 8% of men and 11% of women had blood pressure controlled to < 140/90 mm Hg. The Anglo-Scandinavian cardiac outcomes trial (ASCOT) data show that 87% of non-diabetic patients in the St Mary's Centre are currently treated to below 140/90 mm Hg. These differences can be explained by strict protocol adherence, a focus on cardiovascular disease, longer consultation times and punctual appointments, reinforcement of non-pharmacological advice, and blood pressure readings taken in line with BHS guidelines. Some of these points might be translated into the more challenging setting of primary care.

Indexed as

Adrenergic beta-AntagonistsAmbulatory CareAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsAtorvastatinBlood PressureBlood Pressure DeterminationCoronary DiseaseFemaleHeptanoic AcidsHumansHypertensionMalePyrrolesAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsAtorvastatinHeptanoic AcidsPyrroles

Identifiers

PMID15145911
PMCPMC1876319

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.